RxDoctor Payments Data

Charles Young, MD

Family Medicine · Marshall, NCNPI 1891782322

Payments from drug & device makers

$681in general payments, 2019–2025

Across 32 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$226
  • Lilly USA, LLC$115
  • AbbVie$86
  • Alkermes, Inc.$37
  • Inari Medical, Inc.$36
  • AstraZeneca$31
  • plus $149 from 7 others

What the payments were for

  • Food & beverage$681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$681 in reported general payments places this provider in the 60th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$457
Medicare patients
41
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$107,071
JardianceEmpagliflozin113$91,737
OzempicSemaglutide66$75,433
TrulicityDulaglutide26$36,372
JanuviaSitagliptin Phosphate27$32,165
XareltoRivaroxaban32$25,116
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,466
SymbicortBudesonide/Formoterol Fumarate53$14,286
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$12,068
InvokanaCanagliflozin16$11,700
EntrestoSacubitril/Valsartan16$11,110
Combivent RespimatIpratropium/Albuterol Sulfate17$10,129
Tresiba Flextouch U-100Insulin Degludec21$9,516
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$7,223
LinzessLinaclotide12$6,321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$226$75,43366 claims
Lilly USA, LLCTrulicity$115$36,37226 claims
AstraZenecaSymbicort$31$14,28653 claims
AbbVieLinzess, Synthroid$86$7,43433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Marshall

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →